Author
Robert Moskowitz
Bio: Robert Moskowitz is an academic researcher from Montefiore Medical Center. The author has contributed to research in topics: Heart failure & Acute decompensated heart failure. The author has an hindex of 3, co-authored 5 publications receiving 562 citations.
Papers
More filters
••
NewYork–Presbyterian Hospital1, New York Hospital Queens2, Jacobi Medical Center3, Beth Israel Medical Center4, Mount Sinai Hospital5, Lincoln Hospital6, Valley Hospital7, Montefiore Medical Center8, Bronx-Lebanon Hospital Center9, Mercy Medical Center (Baltimore, Maryland)10, Albert Einstein College of Medicine11
TL;DR: Patients hospitalized for heart failure with a normal ejection fraction are most often chronically incapacitated elderly women with a history of hypertension and increased LV mass, and reasons for clinical decompensation are identified in only one-half of patients.
382 citations
••
TL;DR: Though women are treated less aggressively, treatment gaps exists in both sexes, and length of stay and in-hospital mortality rates are similar, more women than men are hospitalized with ADHF.
192 citations
••
TL;DR: Theoretic considerations underlying the potential antagonistic interaction between ACE inhibitors and aspirin in patients with heart failure has become the focus of both increasing research and intense debate and is highlighted in this article.
Abstract: Angiotensin-converting enzyme (ACE) inhibitors have become the cornerstone of therapy for congestive heart failure (CHF). Because ischemic heart disease is the most common cause of CHF, aspirin is frequently given concomitantly with ACE inhibitors in patients with CHF. Increased bradykinin levels, with the consequent enhanced synthesis of vasodilatory prostaglandins, appear to mediate a significant benefit of ACE inhibitor therapy in these patients. In contrast, aspirin inhibits cyclooxygenase, and thereby suppresses prostaglandin production. Thus, these counteracting effects on prostaglandins may result in antagonism between ACE inhibitor and aspirin therapy in heart failure patients. Several early reports questioned the safety of aspirin in CHF, and the potential antagonistic interaction between ACE inhibitors and aspirin in patients with heart failure has become the focus of both increasing research and intense debate. This article briefly highlights the theoretic considerations underlying this interaction, and reviews the available evidence for such an interaction from clinical trials.
3 citations
Cited by
More filters
••
TL;DR: Theodore G. Feldman, MD, PhD, FACC, FAHA, Chair as mentioned in this paper, Chair, Chair of FAHA 2015, 2016, 2017, 2018, 2019, 2019
Abstract: Mariell Jessup, MD, FACC, FAHA, Chair [*][1]
William T. Abraham, MD, FACC, FAHA[†][2]
Donald E. Casey, MD, MPH, MBA[‡][3]
Arthur M. Feldman, MD, PhD, FACC, FAHA[§][4]
Gary S. Francis, MD, FACC, FAHA[§][4]
Theodore G. Ganiats, MD[∥][5]
Marvin A. Konstam, MD, FACC[¶][6]
Donna M.
3,542 citations
••
VU University Medical Center1, Charité2, Keele University3, University of Erlangen-Nuremberg4, Katholieke Universiteit Leuven5, University of Eastern Piedmont6, Oslo University Hospital7, University of Porto8, University of Debrecen9, Maastricht University10, University of Göttingen11, Stavanger University Hospital12, Cardiff University13
TL;DR: The updated strategies for the diagnosis and exclusion of HFNEF are useful not only for individual patient management but also for patient recruitment in future clinical trials exploring therapies forHFNEF.
Abstract: Diastolic heart failure (DHF) currently accounts for more than 50% of all heart failure patients. DHF is also referred to as heart failure with normal left ventricular (LV) ejection fraction (HFNEF) to indicate that HFNEF could be a precursor of heart failure with reduced LVEF. Because of improved cardiac imaging and because of widespread clinical use of plasma levels of natriuretic peptides, diagnostic criteria for HFNEF needed to be updated. The diagnosis of HFNEF requires the following conditions to be satisfied: (i) signs or symptoms of heart failure; (ii) normal or mildly abnormal systolic LV function; (iii) evidence of diastolic LV dysfunction. Normal or mildly abnormal systolic LV function implies both an LVEF > 50% and an LV end-diastolic volume index (LVEDVI) 16 mmHg or mean pulmonary capillary wedge pressure >12 mmHg) or non-invasively by tissue Doppler (TD) (E/E' > 15). If TD yields an E/E' ratio suggestive of diastolic LV dysfunction (15 > E/E' > 8), additional non-invasive investigations are required for diagnostic evidence of diastolic LV dysfunction. These can consist of blood flow Doppler of mitral valve or pulmonary veins, echo measures of LV mass index or left atrial volume index, electrocardiographic evidence of atrial fibrillation, or plasma levels of natriuretic peptides. If plasma levels of natriuretic peptides are elevated, diagnostic evidence of diastolic LV dysfunction also requires additional non-invasive investigations such as TD, blood flow Doppler of mitral valve or pulmonary veins, echo measures of LV mass index or left atrial volume index, or electrocardiographic evidence of atrial fibrillation. A similar strategy with focus on a high negative predictive value of successive investigations is proposed for the exclusion of HFNEF in patients with breathlessness and no signs of congestion. The updated strategies for the diagnosis and exclusion of HFNEF are useful not only for individual patient management but also for patient recruitment in future clinical trials exploring therapies for HFNEF.
2,578 citations
••
TL;DR: Global HHF registries are reviewed to describe the patient characteristics, management, outcomes and their predictors, quality improvement initiatives, regional differences, and limitations of the available data and propose a roadmap for the design and conduct of future H HF registries.
1,604 citations
••
TL;DR: The 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and This information is current as of August 30, 2010 http://content.onlinejacc.org/cgi/content/full/53/15/1343 located on the World Wide Web at: The online version of this article, along with updated information and services, is
Abstract: 2009;53;1343-1382; originally published online Mar 26, 2009; J. Am. Coll. Cardiol. Rahko, Marc A. Silver, Lynne Warner Stevenson, and Clyde W. Yancy Francis, Theodore G. Ganiats, Marvin A. Konstam, Donna M. Mancini, Peter S. Mariell Jessup, William T. Abraham, Donald E. Casey, Arthur M. Feldman, Gary S. Heart and Lung Transplantation Developed in Collaboration With the International Society for Guidelines Cardiology Foundation/American Heart Association Task Force on Practice Management of Heart Failure in Adults: A Report of the American College of 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and This information is current as of August 30, 2010 http://content.onlinejacc.org/cgi/content/full/53/15/1343 located on the World Wide Web at: The online version of this article, along with updated information and services, is
1,201 citations
••
TL;DR: European guidelines on cardiovascular disease prevention in clinical practice: Executive summary authors/Task Force Members.
1,200 citations